Stage IV ER-positive/HER2-negative breast cancer with synchronous gastric and bone metastases

This breast cancer diagnosis at a glance

Stage at diagnosis
Stage IV
Subtype
Invasive Lobular Carcinoma
Biomarkers
Gastric metastasis showed ER-positive, PR-negative, HER2 0 lobular breast cancer. Breast primary was ER/PR-positive, HER2-negative, Ki-67 5%.
Sex
Female
Spread to
bone; stomach/gastric
Treatment
hormone therapy, targeted therapy and supportive care
Outcome
Responding Well

Treatment course, step by step

  1. Started palliative systemic therapy with anastrozole plus palbociclib for ER-positive/HER2-negative metastatic breast cancer
  2. Proton pump inhibitor therapy was used for upper-GI symptoms
  3. At 2 months, CT looked similar, with persistent widespread bone metastases
  4. Treatment was tolerated without early complications.

What happened, in summary

This 78-year-old woman sought care for chronic belching, dyspepsia, daily nausea, intermittent melena, vomiting, and post-meal epigastric pain. She had never undergone screening mammography and had no known family history of breast or colorectal cancer. Endoscopy showed erosive mucosal change along the lesser curvature of the stomach and a small peripyloric opening, and biopsy of that subtle gastric abnormality revealed metastatic carcinoma favoring a breast primary. Immunohistochemistry in the gastric biopsy showed an invasive lobular pattern with strong ER positivity at 95%, PR negativity below 1%, HER2 0, and E-cadherin loss. Mammography and ultrasound then found a right breast lesion with right axillary lymphadenopathy. CT showed diffuse mixed osteolytic and sclerotic lesions throughout the axial and appendicular skeleton, consistent with widespread bone metastases. The right breast core biopsy showed grade 2 invasive ductal carcinoma, ER 91-100%, PR 91-100%, HER2 0, and Ki-67 5%. A right axillary lymph-node fine-needle aspiration was positive for malignancy. Together, the findings supported newly diagnosed metastatic breast cancer with a ductal breast primary and gastric metastasis showing lobular features, likely reflecting tumor heterogeneity. She began palliative systemic treatment with anastrozole plus the CDK4/6 inhibitor palbociclib for hormone receptor-positive, HER2-negative metastatic disease. Proton pump inhibitor therapy also helped her upper-GI symptoms. At 2-month follow-up, CT imaging was similar to baseline, with persistent diffuse bone metastases but no early radiographic worsening. She continued to tolerate endocrine and CDK4/6 therapy, and no additional follow-up was available beyond that early stable period. The early result therefore supported disease control and symptom improvement, while still reflecting ongoing Stage IV breast cancer requiring palliative systemic treatment.

Where this story comes from

This is a lay summary of an account first published by PMC / PubMed Central. Read the original in full

How we source and attribute stories Accuracy and limitations

Collections this story belongs to

Similar breast cancer stories

These are lay summaries of published cancer stories, for information only. No two cancers behave the same way, and nothing here predicts your own diagnosis or replaces advice from your oncology team. Read the full disclaimer

Search more breast cancer stories